Aptalis Pharma continued to evaluate its pancreatic enzyme products (PEPs) in patients with cystic fibrosis and exocrine pancreatic insufficiency…
Articles by Maureen Newman
After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004,…
A number of factors influence the health-related quality of life of patients with cystic fibrosis. A new study in…
Vertex Pharmaceuticals‘ two-part proof-of-concept study evaluating ivacaftor (under the name KALYDECO) in 24 cystic fibrosis patients…
A group of thirteen scientists at the University of North Carolina School of Medicine may know why certain cystic…
PTC Therapeutics, Inc. announced unexpected, yet encouraging results of their product ataluren. The biopharmaceutical company focuses on developing small-molecule…
Lexington, Massachusetts-based Pulmatrix made an impact at the 2014 Respiratory Drug Delivery Conference being held in Fajardo, Puerto Rico.
Adding to the excitement of Vertex Pharmaceuticals Inc.‘s new…
Vertex Pharmaceuticals continues to break new ground on developing treatments for the orphan disease cystic fibrosis. Most recently, Vertex received…
An antimicrobial peptide produced by human immune cells may actually promote bacterial survival in cystic fibrosis patients with a…